Post navigation
Previous Post
PharmaIN to Present Promising Interim Data from its Ongoing Phase 1 Trial of PHIN-214, an Optimized Vasopressor for Decompensated Cirrhosis, at The Liver Meeting® 2024
Next Post
PharmaIN Unveils Interim Phase 1b Clinical Data on the Activity and Safety of PHIN-214 in Decompensated Liver Cirrhosis at AASLD – The Liver Meeting® 2024
Related Posts